Patent intelligence · US
US 6599275
Implantable medical device
Implantable medical device
Patent details — US 6599275
- Jurisdiction
- US
- Status
- expired
- Grant date
- Jul 29, 2003
- Expiration
- Jul 24, 2023
- Applicant
- Cook Regentec LLC
- Claims
- 2
- CPC classes
- A61K, A61K51/1282
Quick answer
US 6599275 (Implantable medical device) is held by Cook Regentec LLC. Status: expired. Granted Jul 29, 2003. Expires Jul 24, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cook Regentec LLC
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61K, A61K51/1282
More from Cook Regentec LLC
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 6599275?
US 6599275 (Implantable medical device) is held by Cook Regentec LLC. Status: expired. Granted Jul 29, 2003. Expires Jul 24, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6599275?
Cook Regentec LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 6599275 expire?
Our index shows an expiration date of Jul 24, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.